- Home
- SBRA vs JANX Comparison
SBRA vs JANX Comparison
Compare SBRA & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBRA
- JANX
- Stock Information
- Founded
- SBRA 2010
- JANX 2017
- Country
- SBRA United States
- JANX United States
- Employees
- SBRA N/A
- JANX N/A
- Industry
- SBRA Real Estate Investment Trusts
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- SBRA Real Estate
- JANX Health Care
- Exchange
- SBRA Nasdaq
- JANX Nasdaq
- Market Cap
- SBRA 4.3B
- JANX 3.6B
- IPO Year
- SBRA N/A
- JANX 2021
- Fundamental
- Price
- SBRA $16.95
- JANX $56.83
- Analyst Decision
- SBRA Buy
- JANX Strong Buy
- Analyst Count
- SBRA 6
- JANX 11
- Target Price
- SBRA $19.50
- JANX $83.09
- AVG Volume (30 Days)
- SBRA 2.3M
- JANX 1.7M
- Earning Date
- SBRA 10-31-2024
- JANX 11-06-2024
- Dividend Yield
- SBRA 7.08%
- JANX N/A
- EPS Growth
- SBRA N/A
- JANX N/A
- EPS
- SBRA 0.41
- JANX N/A
- Revenue
- SBRA $682,324,000.00
- JANX $13,049,000.00
- Revenue This Year
- SBRA N/A
- JANX $40.27
- Revenue Next Year
- SBRA $6.59
- JANX N/A
- P/E Ratio
- SBRA $41.56
- JANX N/A
- Revenue Growth
- SBRA 20.53
- JANX 54.12
- 52 Week Low
- SBRA $12.83
- JANX $7.79
- 52 Week High
- SBRA $20.03
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- SBRA 29.64
- JANX 50.66
- Support Level
- SBRA $17.27
- JANX $54.20
- Resistance Level
- SBRA $17.93
- JANX $66.34
- Average True Range (ATR)
- SBRA 0.41
- JANX 5.47
- MACD
- SBRA -0.14
- JANX -0.57
- Stochastic Oscillator
- SBRA 6.37
- JANX 15.02
About SBRA Sabra Health Care REIT Inc.
Sabra Health Care REIT Inc is a healthcare facility real estate investment trust. The company operates one segment that owns and invests in healthcare real estate. All of the company's revenue is generated in the United States. Sabra's operations consist of nursing facilities, assisted living centers, and mental health facilities.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to treat patients suffering from cancer.